throbber
Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 1 of 12
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`
`)
`)
`)
`)
`)
`)
`
`)
`) Case No. 1:18-cv-10242-ADB
`)
`
`)
`)
`)
`
`
`
`TEVA PHARMACEUTICALS
`
`
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS USA, INC.
`
`
`
`
`
`
`
`Plaintiffs,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`v.
`
`
`
`
`
`
`
`
`ELI LILLY AND COMPANY
`
`
`
`
`
`
`
`
`
`
`
`Defendant.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`DECLARATION OF STEPHEN H. INGHAM IN SUPPORT OF DEFENDANT ELI
`LILLY AND COMPANY’S MOTION TO EXCLUDE DR. GEOFFREY HALE AS AN
`EXPERT AND PREVENT DISCLOSURE OF PROTECTED INFORMATION
`
`I, Stephen H. Ingham, declare as follows:
`
`
`
`1.
`
`I am a Senior Director and Assistant General Patent Counsel at Eli Lilly and
`
`Company (“Lilly”). I am based in Bracknell, London, United Kingdom. I hold a Bachelor of
`
`Science degree in Biochemistry with Biotechnology from the University of St. Andrews, and a
`
`Master of Science degree in Management of Intellectual Property from the Queen Mary
`
`University of London. I additionally have earned a Diploma in European Patent Litigation from
`
`Université Robert Schuman (Strasbourg III) in Strasbourg, France. I am licensed as a United
`
`Kingdom Patent Attorney by the Chartered Institute of Patent Attorneys, and licensed as a
`
`European Patent Attorney by the European Patent Office. I have personal knowledge of the
`
`matters set forth herein, and if called upon would testify as follows.
`
`2.
`
`Attached hereto as Exhibit 1 is a true and correct copy of a document
`
`
`
`
`
`
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 2 of 12
`
`3.
`
`4.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5.
`
`Attached hereto as Exhibit 2 I believe to be a true and correct copy of
`
`
`
`6.
`
`Attached hereto as Exhibit 3 I believe to be a true and correct copy of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 3 of 12
`
`7.
`
`Attached hereto as Exhibit 4 is a true and correct copy of European Patent No.
`
`1,994,937 B1, entitled “Prevention and treatment of amyloidogenic disease,” assigned on its
`
`
`
`
`
`face to Janssen Alzheimer Immunotherapy Limited.
`
`8.
`
`
`
`
`
`
`
`
`
`Claims 1-3 of the European patent read as follows:
`
`1. A pharmaceutical composition comprising an antibody to Aβ and a
`pharmaceutically acceptable non-toxic carrier or diluent, for use in preventing or
`treating a disease characterized by amyloid deposit in a patient, wherein the
`isotype of the antibody is human IgG1.
`
`2. The pharmaceutical composition for use in preventing or treating a disease
`characterized by amyloid deposit in a patient of claim 1, wherein the antibody is
`a monoclonal antibody.
`
`3. The pharmaceutical composition for use in preventing or treating a disease
`characterized by amyloid deposit in a patient of claim 1, wherein the antibody is
`a humanized antibody or a human antibody.
`
`Ex. 4 at 30:50-57 (emphases in original).
`
`9.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 4 of 12
`
`Attached hereto as Exhibit 5 is a true and correct redacted copy of
`
`
`
`
`
`10.
`
`11.
`
`12.
`
` Lilly
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`opposition to EP1994937, which Lilly filed at the European Patent Office on September 27,
`
`2011, and its UK revocation action, which Lilly filed on September 30, 2011. Attached
`
`hereto as Exhibit 6 is a true and correct copy of Lilly’s Notice of Opposition for European
`
`Patent No. 1,994,937, which I signed as an authorized representative of Lilly. Attached hereto as
`
`Exhibit 7 is a true and correct copy of the minutes of oral proceedings before the European
`
`Patent Office held on June 10, 2013, which I attended on behalf of Lilly. Attached hereto as
`
`4
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 5 of 12
`
`Exhibit 8 is a true and correct copy of the as-filed Claim Form in the English Patents Court
`
`dated September 30, 2011, with a seal from the Court chambers dated October 12, 2011.
`
`13.
`
`Attached hereto as Exhibit 9 is a true and correct redacted copy of
`
`14.
`
`
`
`15.
`
`Attached hereto as Exhibit 10 is a true and correct redacted copy of
`
`
`
`16.
`
`17.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`18.
`
`Attached hereto as Exhibit 11, is what I believe to be a true and correct copy of
`
`
`
`
`
`
`
`5
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 6 of 12
`
`
`
`19.
`
`Attached hereto as Exhibit 12 is a true and correct copy of European Patent
`
`No. 1,641,822 B1, entitled “IL-17 A/F Heterologous Polypeptides and Therapeutic Uses
`
`Thereof,” assigned on its face to Genentech, Inc.
`
`20.
`
`
`
`
`
`
`
`
`
`
`
`21.
`
`Claims 27-28 of EP1641822 as granted read as follows:
`
`27. An isolated antibody which specifically binds to the IL-17A/F heterodimeric complex
`according to Claim 23 or Claim 24 and which inhibits the activity of the IL-17A/F
`heterodimeric complex to induce production of IL-8 and IL-6.
`
`
`28. The isolated antibody of Claim 27, wherein said antibody is a monoclonal antibody,
`a humanized antibody or a single-chain antibody.
`
`Ex. 12 at 93:15-20.
`
`22.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6
`
`

`

`
`
`
`
`
`
`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 7 of 12
`
`25.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`27.
`
`Attached hereto as Exhibit 13 I believe is a true and correct redacted copy of
`
`
`
`
`
`
`
`28.
`
`29.
`
`30.
`
`
`
`
`
`7
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 8 of 12
`
`31.
`
`Attached hereto as Exhibit 15 is a
`
`
`
`32.
`
`Attached hereto as Exhibit 16 is a
`
`33.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`34.
`
`Attached hereto as Exhibit 17 is what I believe is a true and correct redacted copy
`
`of
`
`35.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 9 of 12
`
`37.
`
`Attached hereto as Exhibit 18 is a true and correct redacted copy of a
`
`38.
`
`
`
`
`
`
`
`
`
`
`
`
`
` I understand that Dr. Hale was at one time a non-executive director of Absolute
`
`Antibody Ltd.
`
`39.
`
`
`
`
`
`
`
`of
`
`of
`
`40.
`
`Attached hereto as Exhibit 19 is what I believe is a true and correct redacted copy
`
`41.
`
`Attached hereto as Exhibit 20 is what I believe is a true and correct redacted copy
`
`
`
`
`
`42.
`
`
`
`9
`
`
`
`
`
`
`
`
`
`
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 10 of 12
`
`43.
`
`Attached hereto as Exhibit 21 is a true and correct copy of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`44.
`
`45.
`
`Attached hereto as Exhibit 22 is a true and correct copy of
`
`
`
`46.
`
`
`
`
`
`47.
`
`Attached hereto as Exhibit 23 are true and correct copies of documents
`
`
`
`
`
`
`
`
`
`10
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 11 of 12
`
`48.
`
`Attached hereto as Exhibit 24 are true and correct copies of documents
`
`
`
`
`
`
`
`
`
`49.
`
`I am informed by counsel that Exhibits 1-3, 5, 9-11, and 13-24 to this declaration
`
`are subject to Lilly’s pending Uncontested Motion for Leave to Impound Confidential
`
`Defendant’s Motion to Exclude Dr. Geoffrey Hale as an Expert and Prevent Disclosure of
`
`Protected Information and Exhibits (ECF No. 180) and will be provisionally filed under seal.
`
`50.
`
`Complete copies of any excerpted and/or redacted documents identified above
`
`will be provided to the Court upon request.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`11
`
`

`

`Case 1:18-cv-12029-ADB Document 198 Filed 10/20/21 Page 12 of 12
`Executed on this 12th day of October, 2021, in London, United Kingdom.
`
`Ayob
`
`Stephen H. Ingham
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket